Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan-Reference-Cited by-同舟云学术

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan

Published:2020-10 Issue:10 Volume:8 Page:811-818
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Solomon Scott D.,Jhund Pardeep S.,Claggett Brian L.,Dewan Pooja,Køber Lars,Kosiborod Mikhail N.,Martinez Felipe A.,Ponikowski Piotr,Sabatine Marc S.,Inzucchi Silvio E.,Desai Akshay S.,Bengtsson Olof,Lindholm Daniel,Sjostrand Mikaela,Langkilde Anna Maria,McMurray John J.V.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference9 articles.

1. Heart failure drug treatment;Rossignol;Lancet,2019

2. Angiotensin-neprilysin inhibition versus enalapril in heart failure;McMurray;N Engl J Med,2014

3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

4. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

5. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and economic analysis of the use of dapagliflozin in patients with chronic heart failure with reduced left ventricular ejection fraction in various subgroups of standard therapy in the Russian Federation;Terapevticheskii arkhiv;2024-09-14

2. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

3. Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction;Russian Journal of Cardiology;2024-08-26

4. Eligibility of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction: Insights from the Colombian heart failure registry (RECOLFACA);IJC Heart & Vasculature;2024-08

5. A Review of Contemporary and Future Pharmacotherapy for Chronic Heart Failure in Children;Children;2024-07-16